Efficacy and safety of belumosudil for refractory chronic graft-versus-host disease in routine practice

Key Points

• Belumosudil shows significant efficacy in managing refractory chronic graft-versus-host disease, indicating a promising treatment option.
• The analysis indicates an improvement in symptoms for at least 60% of patients receiving belumosudil.
• Assessments were conducted through routine clinical practice, ensuring applicability to real-world settings.
• The findings highlight the need for additional, more extensive studies to confirm these results in diverse populations.